Snider B Joy, Buckles Virginia D
Washington University, Campus Box 8111 BT 229, 660 S Euclid Ave, St Louis, MO 63110, USA.
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):470-4. doi: 10.1212/01.CON.0000429171.50686.07.
This article presents the case of a cognitively normal patient who is requesting a procedure (amyloid imaging) recently approved for the diagnosis of Alzheimer disease (AD) in patients with cognitive impairment. The predictive value of this test in unaffected people is not clearly established. Knowing the results of the test will have no effect on therapeutic options, although the patient may make lifestyle decisions based on the results. There is potential risk to the patient in terms of insurability, employability, and psychological consequences. Physicians will face this situation with increasing frequency as the AD biomarker field progresses.
本文介绍了一例认知功能正常的患者，该患者要求进行一项最近被批准用于诊断认知障碍患者阿尔茨海默病（AD）的检查（淀粉样蛋白成像）。该检查在未受影响人群中的预测价值尚未明确确立。尽管患者可能会根据检查结果做出生活方式的决定，但了解检查结果对治疗选择并无影响。在保险可及性、就业能力和心理影响方面，患者存在潜在风险。随着AD生物标志物领域的发展，医生将越来越频繁地面临这种情况。
